{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:08:54Z","timestamp":1790719734780,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2001,3,1]],"date-time":"2001-03-01T00:00:00Z","timestamp":983404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2001,3,1]],"date-time":"2001-03-01T00:00:00Z","timestamp":983404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2001,3,1]]},"DOI":"10.1038\/sj.tpj.6500025","type":"journal-article","created":{"date-parts":[[2011,6,13]],"date-time":"2011-06-13T12:58:30Z","timestamp":1307969910000},"page":"204-210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels"],"prefix":"10.1038","volume":"1","author":[{"given":"R","family":"Kerb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A S","family":"Aynacioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Brockm\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Schlagenhaufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Szekeres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hamwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Fritzer-Szekeres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H Z","family":"\u00d6ngen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"G\u00fczelbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Roots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Brinkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2001,10,30]]},"reference":[{"key":"BF6500025_CR1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0022-5347(25)00306-4","volume":"241","author":"S Fritz","year":"1987","unstructured":"Fritz S, Lindner W, Roots I, Frey BM, K\u00fcpfer A . Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans J Pharmacol Exp Ther 1987 241: 615\u2013622","journal-title":"J Pharmacol Exp Ther"},{"key":"BF6500025_CR2","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/S0006-2952(99)00034-9","volume":"57","author":"T Yasumori","year":"1999","unstructured":"Yasumori T, Chen LS, Li QH, Ueda M, Tsuzuki T, Goldstein JA et al. Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19 Biochem Pharmacol 1999 57: 1297\u20131303","journal-title":"Biochem Pharmacol"},{"key":"BF6500025_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1042\/bj2890533","volume":"289","author":"ME Veronese","year":"1993","unstructured":"Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DL et al. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily Biochem J 1993 289: 533\u2013538","journal-title":"Biochem J"},{"key":"BF6500025_CR4","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0026-895X(25)09788-3","volume":"46","author":"SM De Morais","year":"1994","unstructured":"De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA . Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese Mol Pharmacol 1994 46: 594\u2013598","journal-title":"Mol Pharmacol"},{"key":"BF6500025_CR5","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","volume":"269","author":"SM De Morais","year":"1994","unstructured":"De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA . The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans J Biol Chem 1994 269: 15419\u201315422","journal-title":"J Biol Chem"},{"key":"BF6500025_CR6","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0022-3565(24)37213-1","volume":"284","author":"RJ Ferguson","year":"1998","unstructured":"Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin J Pharmacol Exp Ther 1998 284: 356\u2013361","journal-title":"J Pharmacol Exp Ther"},{"key":"BF6500025_CR7","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1111\/j.1528-1157.1998.tb01330.x","volume":"39","author":"K Mamiya","year":"1998","unstructured":"Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, Yamada H et al. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics Epilepsia 1998 39: 1317\u20131323","journal-title":"Epilepsia"},{"key":"BF6500025_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0009-9236(97)90031-X","volume":"62","author":"A Odani","year":"1997","unstructured":"Odani A, Hashimoto Y, Otsuki Y, Uwai Y, Hattori H, Furusho K et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy Clin Pharmacol Ther 1997 62: 287\u2013292","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500025_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","volume":"455","author":"RL Juliano","year":"1976","unstructured":"Juliano RL, Ling V . A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biochim Biophys Acta 1976 455: 152\u2013162","journal-title":"Biochim Biophys Acta"},{"key":"BF6500025_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1046\/j.1432-1327.1998.2510252.x","volume":"251","author":"A Seelig","year":"1998","unstructured":"Seelig A . A general pattern for substrate recognition by P-glycoprotein Eur J Biochem 1998 251: 252\u2013261","journal-title":"Eur J Biochem"},{"key":"BF6500025_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1146\/annurev.pharmtox.39.1.361","volume":"39","author":"SV Ambudkar","year":"1999","unstructured":"Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM . Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu Rev Pharmacol Toxicol 1999 39: 361\u2013398","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"BF6500025_CR12","doi-asserted-by":"publisher","first-page":"7735","DOI":"10.1073\/pnas.84.21.7735","volume":"84","author":"F Thiebaut","year":"1987","unstructured":"Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC . Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proc Natl Acad Sci U S A 1987 84: 7735\u20137738","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BF6500025_CR13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0021-9258(19)75806-2","volume":"262","author":"K Ueda","year":"1987","unstructured":"Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I . The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation J Biol Chem 1987 262: 505\u2013508","journal-title":"J Biol Chem"},{"key":"BF6500025_CR14","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/38.9.1974900","volume":"38","author":"C Cordon-Cardo","year":"1990","unstructured":"Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR . Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues J Histochem Cytochem 1990 38: 1277\u20131287","journal-title":"J Histochem Cytochem"},{"key":"BF6500025_CR15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0022-3565(24)39245-6","volume":"293","author":"MF Fromm","year":"2000","unstructured":"Fromm MF . P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs J Pharmacol Exp Ther 2000 293: 376\u2013382","journal-title":"J Pharmacol Exp Ther"},{"key":"BF6500025_CR16","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","volume":"97","author":"S Hoffmeyer","year":"2000","unstructured":"Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockm\u00f6ller J Johne A et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci U\u2009S\u2009A 2000 97: 3473\u20133478","journal-title":"Proc Natl Acad Sci U\u2009S\u2009A"},{"key":"BF6500025_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1046\/j.1365-2125.1999.00012.x","volume":"48","author":"AS Aynacioglu","year":"1999","unstructured":"Aynacioglu AS, Brockm\u00f6ller J, Bauer S, Sachse C, G\u00fczelbey P, \u00d6ngen Z et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin Br J Clin Pharmacol 1999 48: 409\u2013415","journal-title":"Br J Clin Pharmacol"},{"key":"BF6500025_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1053\/cp.1999.v66.100072001","volume":"66","author":"AS Aynacioglu","year":"1999","unstructured":"Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schr\u00f6der T et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population Clin Pharmacol Ther 1999 66: 185\u2013192","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500025_CR19","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/00008571-199610000-00007","volume":"6","author":"MJ Stubbins","year":"1996","unstructured":"Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR . Genetic analysis of the human cytochrome P450 CYP2C9 locus Pharmacogenetics 1996 6: 429\u2013439","journal-title":"Pharmacogenetics"},{"key":"BF6500025_CR20","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1006\/bbrc.1998.9992","volume":"254","author":"U Yasar","year":"1999","unstructured":"Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sj\u00f6quist E . Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population Biochem Biophys Res Commun 1999 254: 628\u2013631","journal-title":"Biochem Biophys Res Commun"},{"key":"BF6500025_CR21","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/00007691-200004000-00016","volume":"22","author":"H Ninomiya","year":"2000","unstructured":"Ninomiya H, Mamiya K, Matsuo S, Ieiri I, Higuchi S, Tashiro N . Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication Ther Drug Monit 2000 22: 230\u2013232","journal-title":"Ther Drug Monit"},{"key":"BF6500025_CR22","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000028403","volume":"61","author":"J Brockm\u00f6ller","year":"2000","unstructured":"Brockm\u00f6ller J, Cascorbi I, Henning S, Meisel C, Roots I . Molecular genetics of cancer susceptibility Pharmacology 2000 61: 212\u2013227","journal-title":"Pharmacology"},{"key":"BF6500025_CR23","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/j.1440-1681.1996.tb01154.x","volume":"23","author":"M Eichelbaum","year":"1996","unstructured":"Eichelbaum M, Evert B . Influence of pharmacogenetics on drug disposition and response Clin Exp Pharmacol Physiol 1996 23: 983\u2013985","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"BF6500025_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/00008571-199702000-00007","volume":"7","author":"CR Bhasker","year":"1997","unstructured":"Bhasker CR, Miners JO, Coulter S, Birkett DJ . Allelic and functional variability of cytochrome P4502C9 Pharmacogenetics 1997 7: 51\u201358","journal-title":"Pharmacogenetics"},{"key":"BF6500025_CR25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1046\/j.1365-2125.1997.00572.x","volume":"43","author":"I Ieiri","year":"1997","unstructured":"Ieiri I, Mamiya K, Urae A, Wada Y, Kimura M, Irie S et al. Stereoselective 4\u2032 hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese Br J Clin Pharmacol 1997 43: 441\u2013445","journal-title":"Br J Clin Pharmacol"},{"key":"BF6500025_CR26","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S0959-437X(96)80091-8","volume":"6","author":"MM Gottesman","year":"1996","unstructured":"Gottesman MM, Pastan I, Ambudkar SV . P-glycoprotein and multidrug resistance Curr Opin Genet Dev 1996 6: 610\u2013617","journal-title":"Curr Opin Genet Dev"},{"key":"BF6500025_CR27","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood.V91.5.1749","volume":"91","author":"LA Mickley","year":"1998","unstructured":"Mickley LA, Lee JS, Weng Z, Zhan Z, Alvarez M, Wilson W et al. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors Blood 1998 91: 1749\u20131756","journal-title":"Blood"},{"key":"BF6500025_CR28","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/00008571-200010000-00002","volume":"10","author":"AH Schinkel","year":"2000","unstructured":"Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins Pharmacogenetics 2000 10: 583\u2013590","journal-title":"Pharmacogenetics"},{"key":"BF6500025_CR29","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1172\/JCI118214","volume":"96","author":"AH Schinkel","year":"1995","unstructured":"Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P . Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A J Clin Invest 1995 96: 1698\u20131705","journal-title":"J Clin Invest"},{"key":"BF6500025_CR30","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1172\/JCI118699","volume":"97","author":"AH Schinkel","year":"1996","unstructured":"Schinkel AH, Wagenaar E, Mol CA, van Deemter L . P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs J Clin Invest 1996 97: 2517\u20132524","journal-title":"J Clin Invest"},{"key":"BF6500025_CR31","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S0887-8994(99)00074-0","volume":"21","author":"A Lazarowski","year":"1999","unstructured":"Lazarowski A, Sevlever G, Taratuto A, Massaro M, Rabinowicz A . Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy Pediatr Neurol 1999 21: 731\u2013734","journal-title":"Pediatr Neurol"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/6500025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/6500025","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/6500025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T04:20:40Z","timestamp":1741234840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6500025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3,1]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,3,1]]}},"alternative-id":["BF6500025"],"URL":"https:\/\/doi.org\/10.1038\/sj.tpj.6500025","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,3,1]]},"assertion":[{"value":"26 January 2001","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2001","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2001","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2001","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}